FABMID

#Industrial Biotech

• Cell therapy
• Gene therapy
• Non-viral vector
• Cell transfection
• CAR-T cells
• Bioproduction

BACKGROUND

Fabmid has been incorporated in 2020 with the aim of providing novel skills and experience in the development of cell & gene therapies.
Andrey PICHUGIN (PhD, former leader of a public research lab and Founder of Fabmid SAS) developed a method to produce the first circular vector DNA molecules covalently bound with delivery vehicles of choice that target the vector to cellular nucleus.

DESCRIPTION OF THE PRODUCTS / SERVICES / TECHNOLOGY
Fabmid SAS develops safe and efficient solutions for the growing markets of cell & gene therapies. The company aims to ensure the efficient production of CAR-T-cells for helping millions of patients heal from solid and blood cancers.

Fabmid’s products: (1) circular DNA molecules covalently bound with aptamers for targeted vector delivery into cell nucleus and (2) technological platform for the vector production.

COLLABORATIONS SOUGHT

• Biopharma developing cell or gene therapy.
• Academic laboratories and/or biotech companies experimenting in the field of oncology, immunology, cell&gene therapy, virology…

• Further information

  Our competitive advantages:
  

  • Scalable production on a GMP-compliant technological platform, which belongs to emerging cell-free technologies for the generation of synthetic DNA vectors;
  • Transportation and storage of degradation-resistant vector is compatible with flexible logistics schemes;
  • Highest safety features of the vector include a low error-rate in the DNA sequences, no innate immune response against the vector and prevention of integration into the patient’s genome;
  • Clinical application of the modular “lego-like” vector can be designed for repetitive administrations and persistent transgene expression in dividing cells of patients;
  • Economic models may be implemented at an affordable cost for CAR-T cells treatment of cancers and for other gene therapies.

  2 Patents
  

  Strengths:
  A cutting-edge technology for numerous applications, a very large market and a complementary team.

  Innovation Assets:
  A robust technology, highly valuable for clinical application and scalable for industrial production.